| Expression pattern: |
UP |
| Associated gene: |
c-Myc, LDHA |
| Associated microRNA: |
miR-510-5p |
| Biological function: |
Promotes aerobic glycolysis (Warburg effect) and proliferation in PDAC cells; enhances cell cycle progression; promotes tumor growth in vivo. |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge for miR-510-5p, thereby relieving miR-510-5p-mediated repression of c-Myc and increasing LDHA transcription via c-Myc. |
| Biological pathway or process: |
glycolysis (promotes); proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Western Blot; ChIP / ChIP-seq; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
High circSLIT2 expression is correlated with unfavorable/poor prognosis in PDAC patients. |
| Description: |
circSLIT2 is up-regulated in PDAC and its high expression is associated with poor prognosis. It promotes Warburg-like aerobic glycolysis and proliferation, and enhances tumor growth via a ceRNA mechanism in which circSLIT2 sponges miR-510-5p to increase c-Myc and downstream LDHA transcription. |
| Confidence score: |
0.8763 |